Interaction Between Leucine and Phosphodiesterase 5 Inhibition in Modulating Insulin Sensitivity and Lipid Metabolism by Fu, Lizhi et al.
Georgia State University
ScholarWorks @ Georgia State University
Biology Faculty Publications Department of Biology
2015
Interaction Between Leucine and
Phosphodiesterase 5 Inhibition in Modulating
Insulin Sensitivity and Lipid Metabolism
Lizhi Fu
Georgia State University, lfu1@student.gsu.edu
Fenfen Li
Georgia State University, fli3@student.gsu.edu
Antje Bruckbauer
abruckbauer@nusirt.com
Qiang Cao
Georgia State University, xcui@gsu.edu
Xin Cui
Georgia State University, xcui@gsu.edu
See next page for additional authors
Follow this and additional works at: http://scholarworks.gsu.edu/biology_facpub
Part of the Biology Commons
This Article is brought to you for free and open access by the Department of Biology at ScholarWorks @ Georgia State University. It has been accepted
for inclusion in Biology Faculty Publications by an authorized administrator of ScholarWorks @ Georgia State University. For more information, please
contact scholarworks@gsu.edu.
Recommended Citation
Zemel, Michael, Lizhi Fu, Fenfen Li, Antje Bruckbauer, Qiang Cao, Rui Wu, Hang Shi, Bingzhong Xue, and Xin Cui. 2015.
“Interaction between Leucine and Phosphodiesterase 5 Inhibition in Modulating Insulin Sensitivity and Lipid Metabolism.” Diabetes,
Metabolic Syndrome and Obesity: Targets and Therapy, May, 227. doi:10.2147/DMSO.S82338.
Authors
Lizhi Fu, Fenfen Li, Antje Bruckbauer, Qiang Cao, Xin Cui, Rui Wu, Hang Shi, Bingzhong Xue, and Michael
B. Zemel
This article is available at ScholarWorks @ Georgia State University: http://scholarworks.gsu.edu/biology_facpub/12
© 2015 Fu et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0)  
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further 
permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on 
how to request permission may be found at: http://www.dovepress.com/permissions.php
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2015:8 227–239
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
227
O r i g i n a l  r e S e a r c h
open access to scientific and medical research
Open access Full Text article
http://dx.doi.org/10.2147/DMSO.S82338
interaction between leucine and 
phosphodiesterase 5 inhibition in modulating 
insulin sensitivity and lipid metabolism
lizhi Fu1
Fenfen li1
antje Bruckbauer2
Qiang cao1
Xin cui1
rui Wu1
hang Shi1
Bingzhong Xue1
Michael B Zemel2
1Department of Biology, center for 
Obesity reversal, georgia State 
University, atlanta, ga, 2nuSirt 
Biopharma inc., nashville, Tn, USa
correspondence: Michael B Zemel 
nuSirt Biopharma inc., 11020 Solway 
School road, Suite 109, Knoxville,  
Tn 37931, USa 
Tel +1 865 206 6154 
email mzemel@nusirt.com
Purpose: Leucine activates SIRT1/AMP-activated protein kinase (AMPK) signaling and mark-
edly potentiates the effects of other sirtuin and AMPK activators on insulin signaling and lipid 
metabolism. Phosphodiesterase 5 inhibition increases nitric oxide–cGMP signaling, which in 
turn exhibits a positive feedback loop with both SIRT1 and AMPK, thus amplifying peroxisome 
proliferator-activated receptor γ co-activator α (PGC1α)-mediated effects.
Methods: We evaluated potential synergy between leucine and PDE5i on insulin sensitivity 
and lipid metabolism in vitro and in diet-induced obese (DIO) mice.
Results: Leucine (0.5 mM) exhibited significant synergy with subtherapeutic doses (0.1–10 nM) 
of PDE5-inhibitors (sildenafil and icariin) on fat oxidation, nitric oxide production, and mito-
chondrial biogenesis in hepatocytes, adipocytes, and myotubes. Effects on insulin sensitivity, 
glycemic control, and lipid metabolism were then assessed in DIO-mice. DIO-mice exhibited 
fasting and postprandial hyperglycemia, insulin resistance, and hepatic steatosis, which were 
not affected by the addition of leucine (24 g/kg diet). However, the combination of leucine and 
a subtherapeutic dose of icariin (25 mg/kg diet) for 6 weeks reduced fasting glucose (38%, 
P,0.002), insulin (37%, P,0.05), area under the glucose tolerance curve (20%, P,0.01), and 
fully restored glucose response to exogenous insulin challenge. The combination also inhibited 
hepatic lipogenesis, stimulated hepatic and muscle fatty acid oxidation, suppressed hepatic 
inflammation, and reversed high-fat diet-induced steatosis.
Conclusion: These robust improvements in insulin sensitivity, glycemic control, and lipid 
metabolism indicate therapeutic potential for leucine–PDE5 inhibitor combinations.
Keywords: AMPK, diabetes, icariin, PDE5, sildenafil, SIRT1, steatosis
Introduction
Sirtuin 1 (SIRT1) and AMP-activated protein kinase (AMPK) are well established as 
key sensors of energy status,1–4 sensing energy deprivation via elevations in NAD+ and 
AMP, respectively. Notably, due to their cross-activation, AMPK and SIRT1 are targets 
of common activators and produce overlapping outcomes via stimulation of peroxisome 
proliferator-activated receptor γ co-activator α (PGC1 α) to regulate mitochondrial 
biogenesis and energy expenditure.5,6 The SIRT1–AMPK axis is suppressed in energy 
replete states, including obesity and diabetes, while activation of this axis improves 
hyperglycemia, insulin resistance, and lipid metabolism.7–9
Our previous work demonstrated that the branched chain amino acid l-leucine 
activates SIRT110–13 by lowering its activation energy for NAD+,10 with secondary 
activation of AMPK.11 This shift in SIRT1 sensitivity to NAD+ enables activation 
of this energy sensor at lower NAD+ concentrations, characteristic of energy replete 
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states, and permits coactivation and amplification of other 
compounds that converge on the SIRT1/AMPK axis.10,12 This 
results in significant synergy of leucine with polyphenols 
and with metformin, resulting in significant increases in 
efficacy.10,12–15
Nitric oxide (NO) levels are also responsive to energy 
status and are upregulated during caloric restriction; elevated 
NO, in turn, stimulates SIRT1 activity.16,17 SIRT1, in turn, may 
reciprocally elevate NO levels via deacetylation (Lys 496; 
Lys 506) of endothelial nitric oxide synthase (eNOS)18,19; 
AMPK plays a similar role via phosphorylation of eNOS (Ser 
1177),20,21 resulting in a cross-talk energy-sensing network 
of SIRT1, AMPK, and NO.
The classically established mode of NO action is via 
stimulation of soluble NO-sensitive guanylyl cyclase to 
elevate cGMP and initiate subsequent physiological changes, 
primarily via cGMP-dependent protein kinases (PKGs).22 
Since termination of cGMP signaling is dependent upon 
phosphodiesterase (PDE)-mediated hydrolysis, comparable 
effects are obtained via inhibition of the cGMP-specific PDE5 
with specific inhibitors, such as sildenafil and icariin.22,23 
However, these PDE5-inhibitors also activate eNOS24,25 
and may thereby increase SIRT1 activity and improve lipid 
metabolism and insulin signaling.26–28 Accordingly, our 
objective was to determine whether leucine could synergize 
with PDE5-inhibitors to increase insulin sensitivity and 
lipid metabolism. We tested this synergy with sildenafil as 
a pharmaceutical PDE5 inhibitor and icariin as a naturally 
occurring compound with PDE5 inhibitory activity. Since 
the in vitro results of both were similar, we conducted the 
animal study only with icariin.
Materials and methods
animals and diets
Six-to-eight-week-old male C57/BL6 mice were purchased 
from Jackson Laboratories. Obesity and insulin resistance 
were induced via a high-fat diet (HFD) for 6 weeks. The ani-
mals were then randomized into one of the following groups 
with ten animals per group and kept on their diet for 6 weeks: 
1) control (low-fat diet, standard diet [LabDiet 5001]); 
2) HFD (60% fat; Research Diets, Inc., New Brunswick, NJ, 
USA), 3) HFD + leucine (24 g/kg diet; Sigma-Aldrich Co, 
St Louis, MO, USA), 4) HFD + leucine + icariin (25 mg/kg 
diet; Sigma-Aldrich Co). The leucine dose was designed 
to add a two-fold increase in leucine intake, as previously 
described.12,13 The icariin dose was selected to ensure a 
subtherapeutic dose that would exert no independent effect. 
A survey of the icariin literature indicated typical doses in 
the 50–200 mg/kg body weight range, with no significant 
effect on any variable studied at doses below 10–20 mg/kg 
body weight. For a 30 g mouse consuming ∼3 g chow/day, 
this is equivalent to 100 mg icariin/kg diet. We reduced this 
to 25 mg/kg diet (approximately equivalent to 2.5 mg/kg 
body weight) to ensure no independent effect.
Animals were housed in polypropylene cages at a room 
temperature of 22°C with a 12-hour light/dark cycle. The 
animals had free access to water and their experimental food 
throughout the experiment. Body weight was measured every 
week. Blood glucose was measured in the fed or fasting state 
using a OneTouch Ultra Glucose Meter (LifeScan, Milpitas, 
CA, USA). At the end of the treatment period (6 weeks), all 
animals were humanely euthanized with CO
2
 inhalation. 
Blood and tissues were collected for further experiments as 
described below.
This study and all animal procedures were performed 
under the auspices of an Institutional Animal Care and Use 
Committee-approved protocol of the Georgia State University 
and in accordance with Public Health Service policy and 
recommendations of the Guide.
glucose tolerance test
Mice were in a fasting state overnight (∼16 hours) prior to 
glucose tolerance test. Basal (time 0) blood glucose was 
measured, the mice were then injected intraperitoneally with 
1.2 g glucose/kg body weight, blood glucose was then mea-
sured 15  minutes, 30 minutes, 60 minutes, 90 minutes, and 
120 minutes post-injection, and the area under the glucose 
response curve was calculated.
insulin tolerance test
Food was removed for 4–6 hours prior to initiation of 
insulin tolerance test (ITT). Blood glucose was then 
measured to obtain a time 0 point, and the mice were 
then injected intraperitoneally with 1.0 U insulin/kg body 
weight in ∼0.1 mL 0.9% NaCl. Blood glucose was then 
measured 15 minutes, 30 minutes, 60 minutes, 90 minutes, 
and 120 minutes post-injection, and the change in blood 
glucose over the linear portion of the response curve was 
calculated.
liver histology
Liver tissues were fixed in 10% neutral formalin, embedded 
in paraffin, and cut into 5 µm sections. Sections were pro-
cessed for hematoxylin and eosin staining, and histological 
images were recorded using Nikon Eclipse E800 Microscopy 
with Zeiss AxioCam camera.
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2015:8
Table 1 rT-Pcr probes iD and sequences
ABI assay ID
FaS Mm01204974_m1
ScD1 Mm00772290_m1
cOX1 Mm04225243_g1
acOX1 Mm01246834_m1
cPT1a Mm01231183_m1
cPT1B Mm00487191_g1
il-6 Mm00446190_m1
il-1β Mm01336189_m1
TnFα Mm00443258_m1
McP1 (ccl2) Mm00441242_m1
Forward Reverse Probe
18s agTcccTgcccTTTgTacaca gaTccgagggccTcacTaaac cgcccgTcgcTacTaccgaTTgg
acc gggcTcccTggaTgacaac TTccgggaggagTTcTgga cTcTgaTgaggacccTagTgccggc
PParα gacaaggccTcagggTacca gccgaaTagTTcgccgaaa agcccTTacagccTTcacaTgcgTga
Abbreviations: aBi, applied Biosystems inc (Foster city, ca, USa); rT-Pcr, reverse transcription polymerase chain reaction; FaS, fatty acid synthase; ScD1, stearoyl-coa 
desaturase-1; cOX1, cyclooxygenase 1; acOX1, acyl-coa oxidase; cPT1a, carnitine palmitoyltransferase 1a; cPT1B, carnitine palmitoyltransferase 1B; il-6, interleukin 
6; il-1β, interleukin-1 beta; TnFα, tumor necrosis factor alpha; McP1, monocyte chemotactic protein 1; acc, acetyl coa carboxylase; PParα, peroxisome proliferator-
activated receptor alpha.
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gene expression
Total RNA from liver and gastrocnemius muscle was 
extracted using the Tri-Reagent kit (Molecular Research Cen-
ter, Cincinnati, OH, USA), and gene expression was assessed 
by quantitative reverse transcription-polymerase chain 
reaction (PCR) (ABI Universal PCR Master Mix; Thermo 
Fisher Scientific, Waltham, MA, USA) using a Stratagene 
Mx3000P thermocycler  (Stratagene, La Jolla, CA, USA). The 
gene expression data were normalized to the house keeping 
gene 18s. The primer and probe sets used in the assays were 
purchased from Thermo Fisher Scientific (Waltham, MA, 
USA) and are further described in Table 1.
Plasma biochemistry
Blood was collected via tail vein, and plasma glucose and 
insulin were measured at the indicated time points using the 
glucose assay kit from Cayman Chemical (Ann Arbor, MI, 
USA) and an insulin enzyme linked immunosorbent assay 
kit from EMD Millipore (Billerica, MA, USA). Plasma 
C-reactive protein (CRP) levels were measured in fed mice 
using a mouse CRP enzyme linked immunosorbent assay kit 
(Life Diagnostics, West Chester, PA, USA).
cell culture
Murine 3T3-L1 pre-adipocytes were grown in the absence 
of insulin in Dulbecco’s Modified Eagle’s Medium (DMEM, 
25 mM glucose) containing 10% fetal bovine serum (FBS) 
and antibiotics (1% penicillin-streptomycin) (adipocyte 
medium) at 37°C in 5% CO
2
 in air. Confluent preadipocytes 
were induced to differentiate with a standard differentiation 
medium (DM2-L1; Zen-Bio Inc., Research Triangle Park, 
NC, USA). Preadipocytes were maintained in this differen-
tiation medium for 3 days and subsequently cultured in adi-
pocyte medium for a further 8–10 days to allow at least 90% 
of cells to reach full differentiation before treatment. Media 
was changed every 2–3 days; differentiation was determined 
microscopically via inclusion of fat droplets.
C2C12 myoblasts were plated at a density of 8,000 cells/
cm2 (10 cm2 dish) and grown in DMEM containing 10% 
FBS and antibiotics at 37°C in 5% CO
2
. For differentiation of 
C2C12 cells, cells were grown to 100% confluence, transferred 
to differentiation medium (DMEM with 2% horse serum and 
1% penicillin-streptomycin), and fed with fresh differentiation 
medium every day until myotubes were fully formed (3 days).
Human HepG2 cells (American Type Culture Collection 
HB-8065) were grown and maintained in DMEM, containing 
5.5 mM glucose, 10% FBS, and antibiotics (1% penicillin-
streptomycin) at 37°C in 5% CO
2
 in air. Medium was changed 
every 2–3 days, and cells were subcultured at a ratio of 
1:4–1:6 upon reaching 80% confluence. Lipid accumulation 
was induced by incubation in 25 mM glucose for 48 hours 
prior to treatment.
All cells were obtained from American Type Culture Col-
lection (ATCC, Manassas, VA, USA). Sildenafil, icariin, and 
leucine were obtained from Sigma-Aldrich Co.
Fatty acid oxidation
Palmitate-stimulated oxygen consumption rate was measured 
with an XF 24 analyzer (Seahorse Bioscience, Billerica, MA, 
USA) as previously described10,13 with slight modifications. 
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Figure 1 PDe5-inhibitors combined with leu increases fatty acid oxidation in vitro.
Notes: Differentiated c2c12 muscle cells, 3T3-l1 adipocytes, or hepg2 cells were treated with indicated treatments for 24 hours. Ocr after 200 µM palmitate injection 
(A and C) was measured and the aUc was calculated. (A) Ocr over a 4-hour period in c2c12 muscle cells. (B–D) The calculated aUc of the Ocr expressed as fold change 
compared to control (cells maintained in media without treatments). Data are represented as mean ± SD (n=5). * indicates significant difference to the control (P,0.05).
Abbreviations: PDe5, phosphodiesterase 5; Leu, leucine; OCR, oxygen consumption rate; AUC, area under the curve; Sild, sildenafil; Icar, icariin; SD, standard deviation.
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Cells were seeded at 40,000 cells per well and differenti-
ated as described above. Media was then changed, and the 
cells treated for 24 hours with the indicated treatments, 
washed twice with non-buffered carbonate-free pH 7.4 low 
glucose (2.5 mM) DMEM containing carnitine (0.5 mM), 
equilibrated with 550 µL of the same media in a non-CO
2
 
incubator for 45 minutes, and then inserted into the instru-
ment for 15 minutes of further equilibration, followed by 
O
2
 consumption measurement. Three successive baseline 
measures at 5-minute intervals were taken prior to injection 
of palmitate (200 µM final concentration). Four successive 
5-minute measurements of O
2
 consumption were then con-
ducted, followed by 10-minute re-equilibration and another 
three 5-minute measurements. This measurement pattern was 
then repeated over a 6-hour period.
glucose utilization
In the absence of a fatty acid source and oxidative metabo-
lism, glycolysis and subsequent lactate production results in 
extracellular acidification, which was also measured using 
a Seahorse Bioscience XF24 analyzer. Cells were prepared 
and equilibrated similar to the methods described above for 
fatty acid oxidation, with the exclusion of carnitine from the 
medium. Following instrument equilibration and three base-
line measurements, glucose was injected to a final concen-
tration of 10 mM in each well. Measurements were taken as 
described above utilizing the sensors for extracellular acidifi-
cation rather than O
2
 consumption. Insulin (final concentration 
of 5 nM) was added to some wells as a positive control and to 
some treatment and control wells to assess treatment effects 
on insulin response. The area under the curve of extracellular 
acidification change from baseline for each sample was then 
calculated and used for subsequent analysis.
nO production
NO production was detected using diaminofluorescein-2 diac-
etate (DAF-2DA), as cell-permeable dye, which is hydrolyzed 
by intracellular esterases and thereby trapped within the cell 
as a non-fluorescent dye (DAF-2). NO converts DAF-2 to a 
fluorescent triazole derivative, and fluorescence (excitation 
at 488 nm and emission at 515 nm) is proportional to NO 
 production. DAF-2DA was obtained from Cell Technology, Inc. 
(Mountain View, CA, USA), and fluorescence was measured 
using a microplate reader (Synergy HT; BioTek  Instruments, 
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2015:8
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Figure 2 PDe5-inhibitors combined with leu increases nO production and 
mitochondrial biogenesis in vitro.
Notes: Differentiated c2c12 muscle cells were incubated with or without indicated 
treatments for (A) 4 hours and stained with DaF-2Da for measurement of nO 
production or for (B) 48 hours and stained with the mitochondrial probe naO. 
Data are normalized to cellular protein and expressed as mean ± SeM (n=4–6).
Abbreviations: AFU, arbitrary fluorescence units; DAF-2DA, diaminofluorescein-2 
diacetate; PDe5, phosphodiesterase 5; leu, leucine; naO, 10-n-nonyl-acridine 
orange; NO, nitric oxide; ns, not significant; Sild, sildenafil; Icar, icariin; SEM, 
standard error of the mean.
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Winooski, VT, USA). The intensity of fluorescence was 
expressed as arbitrary units per microgram protein.
Mitochondrial biogenesis
Mitochondrial biogenesis was assessed as change in mito-
chondrial mass, as previously described.12 The mitochon-
drial probe 10-N-nonyl-acridine orange (NAO) (Thermo 
Fisher Scientific, Waltham, MA, USA) was used to analyze 
mitochondrial mass by fluorescence (excitation 485 nm and 
emission 520 nm). Quantitative data were obtained with a 
fluorescence microplate reader (Synergy HT). The intensity of 
fluorescence was expressed as arbitrary units per microgram 
protein and normalized to control values within each assay.
Western blot
Phospho-IRS, IRS, Phospho-Akt, and Akt antibodies 
were obtained from Cell Signaling (Danvers, MA, USA). 
Protein levels of cell extracts were measured by bicin-
choninic acid protein kit (Thermo Fisher Scientific). For 
Western blot, 15 µg protein was resolved on 10% gradient 
polyacrylamide gels (Criterion precast gel; Bio-Rad Labo-
ratories Inc., Hercules, CA, USA), transferred to either 
polyvinylidene fluoride membranes, incubated in blocking 
buffer (5% non-fat dry milk in TBS) and then incubated 
with primary antibody (1:1,000 dilution), washed, and 
incubated with horseradish peroxidase- or fluorescence-
conjugated secondary antibody (1:10,000 dilution). 
Visualization was conducted using Bio-Rad ChemiDoc 
instrumentation and software (Bio-Rad Laboratories) 
and/or band intensity was assessed using Image Lab 4.0 
(Bio-Rad Laboratories), with correction for background 
and loading controls.
Statistical analysis
All data are expressed as mean ± standard error of the mean, 
with the exception of Seahorse fatty acid oxidation, which 
is shown as mean ± standard deviation. Data were analyzed 
by one-way analysis of variance, and significantly different 
group means (P,0.05) were separated by the least significant 
difference test using GraphPad Prism version 6 (GraphPad 
Software, Inc., La Jolla, CA, USA; http://www.graphpad.
com).
Results
in vitro
We initially assessed potential synergy between leucine and 
PDE5-inhibitors in cell culture. Sildenafil dose–response 
curves showed no effects on fat oxidation or glucose utilization 
at concentrations below 10 nM; this is approximately 10% of 
the peak plasma concentration (∼100 nM) achieved in response 
to a low dose (20 mg) of the drug in clinical application. To 
evaluate synergy, this dose was lowered further to 0.1 nM and 
1.0 nM. Icariin dose–response curves were similar to sildenafil, 
so the same concentrations were utilized. While neither PDE5 
inhibitor exerted an independent effect on fat oxidation, both 
interacted with leucine (0.5 mM) to significantly increase fat 
oxidation in C2C12 myotubes, 3T3-L1 adipocytes, and HepG2 
hepatocytes by ∼20%–30% (Figure 1). Both PDE5-inhibitors 
also interacted with leucine to produce modest but significant 
increases in NO production (15%–30%, P,0.0001, Figure 2A) 
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and mitochondrial mass (P,0.03, Figure 2B). Sildenafil also 
exhibited synergy with leucine in stimulating glucose utiliza-
tion in myotubes (∼50%, P,0.04) and adipocytes (∼300%, 
P,0.05) (Figure 3) and in stimulating insulin signaling in 
HepG2 hepatocytes (Figure 4).
in vivo
Six weeks of obesity-induction via HFD caused significant 
weight gain compared to the low-fat diet group; however, there 
was no effect of the treatments on body weight during the 6-week 
treatment period (Figure 5). The HFD also produced significant 
fasting and postprandial hyperglycemia (Figure 6A and C) and 
hyperinsulinemia (Figure 6B and D). Addition of leucine exerted 
no effect on fasting or fed state glucose or on fasting insulin, 
although it did reduce insulin in the fasting state (Figure 6D). 
However, the HFD-induced hyperglycemia was significantly 
attenuated by the addition of leucine + icariin in both the fasting 
and fed states (Figure 6A and C), and the fasting insulinemia 
was also markedly reduced (Figure 6D).
The HFD caused a profound impairment in glucose 
tolerance, which was unaffected by the addition of leucine 
alone but markedly improved by the leucine–icariin com-
bination (Figure 7A). This is reflected in a significant and 
substantial reduction in the area under the glucose toler-
ance curve (P,0.01, Figure 7B). The ITT demonstrates a 
profound blunting of the insulin response in animals on the 
HFD (Figure 7C). Addition of leucine alone exerted no effect 
on insulin tolerance, while the combination of leucine and 
icariin normalized the insulin response, as reflected in the 
ITT curve (Figure 7C) and in the 30-minute change in blood 
glucose (Figure 7D).
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The leucine–icariin combination resulted in upregulation 
of fatty acid oxidation genes in skeletal muscle (Figure 8) 
and liver (Figure 9B) and suppression of hepatic lipogenic 
gene expression (Figure 9A). Moreover, the leucine–icariin 
combination significantly attenuated the HFD-induced 
increase in liver mass (Figure 10A) and completely prevented 
the HFD-induced hepatic lipid accumulation, as shown in 
the liver histology (Figure 10B). The  leucine–icariin com-
bination also suppressed hepatic inflammation, as shown 
by the reduction in hepatic inflammatory genes expression 
(Figure 11).
Discussion
These data indicate that the combination of leucine with 
PDE5 inhibition shifts lipid metabolism from storage to 
oxidation, improves glycemic control, and reverses the 
hepatic steatosis induced by high-fat feeding. These effects 
are similar to those induced by caloric restriction29–34 and 
are likely to be mediated by the same pathways, including 
SIRT1 activation.
Obesity and insulin resistance result in impaired NO 
signaling,35,36 while PDE5-inhibitors, including sildenafil and 
tadalafil, have been demonstrated to increase SIRT1 signaling 
in mice,26,27 to increase energy expenditure in skeletal muscle 
cells,37 to improve energy balance, and to increase insulin 
action in both diet-induced obese (DIO), insulin-resistant 
mice and diabetic patients.28,38 This may be, in part, due to 
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stimulation of eNOS and NO signaling24,25 and subsequent 
NO-mediated SIRT1 activation.26–28
Since leucine activation of SIRT1 results in significant 
augmentation of the effects of other compounds that converge 
on this signaling pathway,10–13 we considered the potential 
for leucine to amplify the effects of PDE5-inhibitors. We 
found leucine to exhibit synergy with subtherapeutic levels 
of both sildenafil and icariin in stimulating fat oxidation in 
skeletal muscle cells, adipocytes, and hepatocytes, as well 
as in stimulating glucose utilization. Moreover, leucine–
sildenafil and leucine–icariin combinations increased NO 
production, possibly due to a combination of direct activation 
of eNOS by the PDE5-inhibitors and indirect eNOS activa-
tion by both SIRT1 and AMPK. This suggests a three-way 
interaction among SIRT1, AMPK, and NO in mediating the 
observed effects, as illustrated in Figure 12. Leucine activa-
tion of SIRT1 results in downstream activation of AMPK,11 
while AMPK in turn activates SIRT1 via phosphorylation 
of NAMPT to regenerate the SIRT1 activator NAD+.39 Both 
AMPK and SIRT1, in turn, activate eNOS via phosphoryla-
tion20,21 and deacetylation,18,19 respectively. The increased 
NO, in turn, may stimulate SIRT1 activity,16,17 resulting in a 
 three-component feed-forward loop.
Data from the mice in the present study are consistent 
with such a multi-component activation. The leucine–icariin 
combination resulted in significant improvements in glyce-
mic control and insulin sensitivity, upregulated fatty acid 
oxidation, and downregulated lipogenic markers, consistent 
with SIRT1–AMPK activation, while the attenuation of 
hepatic lipid accumulation and inflammatory markers may 
be mediated, in part, by both SIRT1 and NO. Reductions in 
SIRT1 activity increases steatosis in response to dietary fat in 
SIRT1+/− mice,40 while SIRT1 activation in DIO-mice results 
in amelioration of hepatic steatosis.15,41,42 On the other hand, 
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Figure 9 leu and icar combination inhibits hepatic lipogenesis and promotes hepatic fatty acid oxidation in DiO-mice.
Notes: (A) gene expression of the lipogenic genes ACC, FAS, and SCD1 and (B) gene expression of genes promoting fatty acid oxidation (PParα, acOX1, cOX1, and cPT1a 
were assessed in liver of DiO-mice fed an hFD with indicated treatments for 6 weeks). Data are expressed as fold change from lFD-control and represented as mean ± 
SeM (n=10).
Abbreviations: leu, leucine; icar, icariin; DiO, diet-induced obese; ACC, acetyl coa carboxylase; FAS, fatty acid synthase; SCD1, stearoyl-coa desaturase-1; PParα, 
peroxisome proliferator-activated receptor alpha; acOX1, acyl-coa oxidase; cOX1, cyclooxygenase 1; cPT1a, carnitine palmitoyltransferase 1a; hFD, high-fat diet; lFD, 
low-fat diet; SEM, standard error of the mean; ns, not significant.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
235
leucine and PDe5 inhibitor interaction
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2015:8
LF
D
HF
D
HF
D +
 Le
u
HF
D +
 Le
u +
 Ic
ar
0
1
2
3
G
ra
m
s
Liver mass
*
P=0.0002 *P=0.03
ns
B
A
LFD
HFD + Leu HFD + Leu + Icar
HFD
Figure 10 leu and icar combination prevents hepatic steatosis in DiO-mice.
Notes: DiO-mice were fed an hFD with indicated treatments for 6 weeks. (A) liver mass and (B) representative liver histology sections to visualize fat accumulation at the 
end of the treatment period are shown. *Significantly different from HFD. Data are presented as means ± SeM (n=10).
Abbreviations: Leu, leucine; Icar, icariin; DIO, diet-induced obese; HFD, high-fat diet; LFD, low-fat diet; SEM, standard error of the mean; ns, not significant.
C-reactive protein
LF
D
HF
D
HF
D +
 Le
u
HF
D +
 Le
u +
 Ic
ar
0
2,000
4,000
6,000
8,000
C
R
P
 (
n
g
/m
L
)
P<0.02 ns
ns
TNFα
LF
D
HF
D
HF
D +
 Le
u
HF
D +
 Le
u +
 Ic
ar0
1
2
3
F
o
ld
 o
f 
co
n
tr
o
l
P<0.03
* *
*P<0.02
ns
IL-1β
LF
D
HF
D
HF
D +
 Le
u
HF
D +
 Le
u +
 
Ica
r
0.0
0.5
1.0
1.5
F
o
ld
 o
f 
co
n
tr
o
l ns
P=0.02
ns
IL-6
LF
D
HF
D
HF
D +
 Le
u
HF
D +
 Le
u +
 Ic
ar
0.0
0.5
1.0
1.5
F
o
ld
 o
f 
co
n
tr
o
l
*
*
*P<0.05
P<0.03
ns
MCP1
LF
D
HF
D
HF
D +
 Le
u
HF
D +
 Le
u +
 Ic
ar
0
1
2
3
4
F
o
ld
 o
f 
co
n
tr
o
l P<0.04
ns
*
*
*P<0.05
BA
EDC
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diet-induced obesity and insulin resistance suppress hepatic 
eNOS activity prior to the induction of hepatic inflammation, 
while increasing NO signaling with sildenafil restored hepatic 
insulin signaling and prevented dietary fat-induced nuclear 
factor-kappaB (NFκB)-mediated hepatic  inflammation.43 
The combination of leucine and icariin in the present study 
resulted in reversal of histological evidence of dietary 
fat-induced hepatic steatosis and normalization of dietary 
fat-induced hepatic TNFα, interleukin 6 (IL-6), and MCP1 
expression and circulating CRP, as well as ∼50% reduction 
in interleukin-1 beta (IL-1β) expression. Thus, our data are 
consistent with a  combination of SIRT1 and NO  signaling, 
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with cross-talk between the two pathways. However, a por-
tion of these effects are likely also mediated via the classi-
cally established mode of PDE5 inhibitor action, mediated 
by extending the duration of cGMP signaling as well as NO 
stimulation of cGMP production via  NO-sensitive guanylyl 
cyclase (Figure 12), resulting in enhanced  cGMP-dependent 
PKG  signaling.22 This further contributes to improvements in 
insulin sensitivity28,44 as well as reductions in hepatic steatosis 
and NFκB-mediated inflammation.36,43,44
Chronic treatment with the PDE5 inhibitor sildenafil 
has been reported to reduce weight gain in HFD-fed mice.28 
In contrast, we found no effects of our treatments on body 
weight (Figure 5). However, we used a much lower dose 
of PDE inhibitor (∼2.5 mg/kg body weight in our study vs 
12 mg/kg BW) and a shorter treatment time (6 weeks in our 
study vs 12 weeks). Moreover, Ayala et al,28 used a preven-
tion approach by starting the sildenafil treatment concomi-
tantly with  beginning of HFD feeding, while in our study, the 
 treatment was added to the HFD after obesity-induction.
In summary, subtherapeutic doses of PDE5-inhibitors com-
bined with leucine result in activation of fatty acid oxidation, 
marked improvement in insulin sensitivity, and reversal of hepatic 
steatosis and inflammation in DIO-mice. We conclude that this 
combination may have therapeutic potential for treatment of both 
non-alcoholic steatohepatitis and type 2 diabetes.
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